| Literature DB >> 32302722 |
Xiong Wang1, Wei Liu2, Jinzhu Zhao3, Yanjun Lu1, Xu Wang1, Caizheng Yu2, Shuhua Hu2, Na Shen1, Weiyong Liu1, Ziyong Sun4, Wengang Li5.
Abstract
More than 1,000 medical workers have been infected with COVID-19 in China. The 80 hospitalized patients included 57 SARS-CoV-2 confirmed and 23 clinically diagnosed. The median age was 39 years, 49 (61.25%) were women, and one patient died. The most common symptoms at onset were fever (65, 81.25%), cough (47, 58.75%), fatigue (28, 35%), myalgia (19, 23.75%), expectoration (19, 23.75%), and diarrhea (15, 18.75%). Patients of frontline medical workers at a single-center hospital showed some unique clinical and laboratory findings compared with other patients in Wuhan and outside of Wuhan. This study provides our experience for other frontline medical workers.Entities:
Keywords: COVID-19; SARS-CoV-2; medical worker; outcome; treatment
Year: 2020 PMID: 32302722 PMCID: PMC7194674 DOI: 10.1016/j.jhin.2020.04.019
Source DB: PubMed Journal: J Hosp Infect ISSN: 0195-6701 Impact factor: 3.926
Clinical characteristics, treatment and outcome of 80 frontline medical staff infected with COVID-19 at a single-centre hospital in Wuhan
| Characteristics | All | SARS-CoV-2 confirmed | Clinically diagnosed | |
|---|---|---|---|---|
| No. | 80 | 57 | 23 | – |
| Age (years) | 39 (32–48.5) | 40 (33–49) | 39 (32–48) | 0.953 |
| Sex (%) | ||||
| Male | 31 (38.75) | 25 (43.86) | 6 (26.09) | 0.139 |
| Female | 49 (61.25) | 32 (56.14) | 17 (73.91) | |
| Composition (%) | ||||
| Doctor | 23 (28.75) | 19 (33.33) | 4 (17.39) | 0.248 |
| Nurse | 41 (51.25) | 26 (45.61) | 15 (65.22) | |
| Other | 16 (20.00) | 12 (21.05) | 4 (17.39) | |
| Comorbidities (%) | ||||
| Hypertension | 10 (12.50) | 9 (15.79) | 1 (4.35) | 0.161 |
| Diabetes | 1 (1.25) | 1 (1.75) | 0 | 0.523 |
| Cardiovascular disease | 2 (2.50) | 1 (1.75) | 1 (4.35) | 0.501 |
| Cerebrovascular disease | 1 (1.25) | 1 (1.75) | 0 | 0.523 |
| Chronic obstructive pulmonary disease | 1 (1.25) | 1 (1.75) | 0 | 0.523 |
| Renal disease | 3 (3.75) | 2 (3.51) | 1 (4.35) | 0.858 |
| Liver disease | 2 (2.50) | 2 (3.51) | 0 | 0.363 |
| Symptoms (%) | ||||
| Fever | 65 (81.25) | 48 (84.21) | 17 (73.91) | 0.286 |
| Fatigue | 28 (35.00) | 23 (40.35) | 5 (21.74) | 0.114 |
| Myalgia | 19 (23.75) | 17 (29.82) | 2 (8.70) | 0.044 |
| Cough | 47 (58.75) | 28 (49.12) | 19 (82.61) | 0.006 |
| Expectoration | 19 (23.75) | 10 (17.54) | 9 (39.13) | 0.040 |
| Diarrhoea | 15 (18.75) | 9 (15.79) | 6 (26.09) | 0.286 |
| Headache | 8 (10.00) | 7 (12.28) | 1 (4.35) | 0.284 |
| Time from onset to hospital admission (days) | 7 (4–8) | 7 (3–10) | 6 (4–8) | 0.936 |
| Admission to intensive care unit | 4 (5.00) | 3 (5.26) | 1 (4.35) | 0.804 |
| Acute respiratory distress syndrome | 4 (5.00) | 2 (3.51) | 2 (8.70) | 0.335 |
| Treatment | ||||
| Antiviral treatment | 78 (97.50) | 56 (98.25) | 22 (95.65) | 0.501 |
| Antibiotics | 75 (93.75) | 52 (91.23) | 23 (100.00) | 0.142 |
| Corticosteroid | 46 (57.50) | 34 (59.65) | 12 (52.17) | 0.540 |
| Non-invasive ventilation | 68 (85.00) | 48 (84.21) | 20 (86.96) | 0.756 |
| Invasive mechanical ventilation | 2 (2.50) | 2 (3.51) | 0 | 0.363 |
| Extracorporeal membrane | 2 (2.50) | 2 (3.51) | 0 | 0.363 |
| Outcome | ||||
| Discharge | 78 (97.50) | 55 (96.49) | 23 (100.00) | 0.359 |
| Death | 1 (1.25) | 1 (1.75) | 0 | 0.523 |
| Hospitalization day | 20.5 (15–28) | 21 (17–28) | 18 (15–30) | 0.297 |
Median (interquartile range).
Laboratory findings on 80 frontline medical staff infected with COVID-19 on hospital admission
| Variables | All | SARS-CoV-2 confirmed ( | Clinically diagnosed ( | Reference | ||
|---|---|---|---|---|---|---|
| Wilcoxon rank-sum test | χ2-test | |||||
| White blood cell count (×109/L) | 4.38 (3.58–5.53) | 4.31 (3.49–5.27) | 4.90 (3.64–5.73) | 3.50–9.50 | 0.253 | 0.231 |
| Increased | 5 (6.25%) | 2 (3.51%) | 3 (13.04%) | |||
| Decreased | 19 (23.75%) | 15 (26.32%) | 4 (17.39%) | |||
| Neutrophil count (×109/L) | 2.55 (2.01–3.66) | 2.43 (1.97–3.55) | 2.86 (2.18–3.83) | 1.80–6.30 | 0.401 | 0.714 |
| Increased | 8 (10.00%) | 5 (8.77%) | 3 (13.04%) | |||
| Decreased | 14 (17.50%) | 11 (19.30%) | 3 (13.04%) | |||
| Lymphocyte count (×109/L) | 1.12 (0.83–1.59) | 1.09 (0.76–1.49) | 1.33 (1.04–1.88) | 1.10–3.20 | 0.019 | 0.148 |
| Increased | – | – | – | |||
| Decreased | 38 (47.50%) | 30 (52.63%) | 8 (34.78%) | |||
| Monocyte count (×109/L) | 0.41 (0.32–0.53) | 0.41 (0.32–0.52) | 0.41 (0.33–0.53) | 0.10–0.60 | 0.861 | 0.704 |
| Increased | 12 (15.00%) | 8 (14.04%) | 4 (17.39%) | |||
| Decreased | – | – | – | |||
| Platelet count (×109/L) | 181.5 (148.00–227.50) | 180.00 (148.00–218.00) | 212.00 (148.00–260.00) | 125.0–350.0 | 0.339 | 0.827 |
| Increased | 3 (3.75%) | 2 (3.51%) | 1 (4.35%) | |||
| Decreased | 8 (10.00%) | 5 (8.77%) | 3 (13.04%) | |||
| D-dimer (mg/L) | 0.40 (0.29–0.58) | 0.40 (0.29–0.57) | 0.40 (0.27–0.59) | <0.22 | 0.864 | – |
| Increased | – | – | – | |||
| Decreased | – | – | – | |||
| Prothrombin time (s) | 14.00 (12.90–14.00) | 13.30 (12.90–14.00) | 13.70 (13.00–14.00) | 11.5–14.5 | 0.469 | 0.909 |
| Increased | 12 (15.00%) | 8 (14.04%) | 4 (17.39%) | |||
| Decreased | 3 (3.75%) | 2 (3.51%) | 1 (4.35%) | |||
| Activated partial thromboplastin time (s) | 41.80 (37.20–44.10) | 42.60 (37.70–44.10) | 40.35 (35.50–43.90) | 29.0–42.0 | 0.174 | 0.880 |
| Increased | – | – | – | |||
| Decreased | 13 (26.53%) | 8 (25.81%) | 5 (27.78%) | |||
| Creatinine (μmol/L) | 63.00 (51.00–84.00) | 73.00 (56.00–84.00) | 54.00 (47.00–86.00) | 45–84 | 0.051 | 0.907 |
| Increased | 19 (23.75%) | 13 (22.81%) | 6 (26.09%) | |||
| Decreased | 6 (7.50%) | 4 (7.02%) | 2 (8.70%) | |||
| Creatine kinase (U/L) | 78.50 (49.00–151.00) | 77.00 (49.00–155.00) | 81.50 (42.00–122.00) | 18–198 | 0.721 | 0.962 |
| Increased | 8 (10.00%) | 6 (10.53%) | 2 (8.70%) | |||
| Decreased | 30 (37.5%) | 21 (36.84%) | 9 (39.13%) | |||
| Lactate dehydrogenase (U/L) | 208.00 (185.00–266.00) | 205.00 (183.00–253.00) | 216.00 (190.00–296.00) | 135–214 | 0.376 | 0.587 |
| Increased | 37 (46.25%) | 25 (43.86%) | 12 (52.17%) | |||
| Decreased | 2 (2.50%) | 1 (1.75%) | 1 (4.35%) | |||
| Alanine aminotransferase (U/L) | 18.00 (12.00–26.00) | 18.50 (12.00–26.00) | 16.00 (12.00–27.00) | ≤33 | 0.821 | 0.505 |
| Increased | 14 (17.50%) | 11 (19.30%) | 3 (13.04%) | |||
| Decreased | – | – | – | |||
| Aspartate aminotransferase (U/L) | 22.00 (18.00–32.00) | 23.50 (19.50–33.00) | 21.00 (17.00–29.00) | ≤32 | 0.214 | 0.560 |
| Increased | 21 (26.25%) | 16 (28.07%) | 5 (21.74%) | |||
| Decreased | – | – | – | |||
| Bilateral involvement on chest radiographs | 79 (98.75%) | 56 (98.25%) | 23 (100.00%) | 0.522 | ||
Mean (SD).